Andreas Saltos, MD
Medical Oncology · Tampa, FLNPI 1679849582
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,706 of the $21,391 with a category attached, or 64.1%. 10 manufacturers reported payments, led by Eli Lilly at 28.2% of the total. 2024 is the largest year on record at $7,841, more than ten times the $23 reported in 2019.
Across 15 payments — averaging $1426.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6K
- Daiichi Sankyo Inc.$6K
- Boehringer Ingelheim$4K
- Pfizer$1K
- Johnson & Johnson$1K
- Lilly USA, LLC$1K
- plus $1K from 4 others
Across 277 payments — averaging $6990.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$890K
- Daiichi Sankyo Inc.$352K
- Genentech, Inc.$339K
- Regeneron$187K
- AstraZeneca$53K
- Janssen Research & Development, LLC$47K
- plus $69K from 6 others
What the payments were for
- Consulting fees$13,70664%
- Speaking & faculty fees$7,44035%
- Travel & lodging$400%
- Food & beverage$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $6,040 |
| Daiichi Sankyo Inc. | 4 | $5,803 |
| Boehringer Ingelheim | 1 | $4,400 |
| Pfizer | 1 | $1,440 |
| Johnson & Johnson | 1 | $1,350 |
| Lilly USA, LLC | 1 | $1,150 |
| Bayer | 1 | $1,028 |
| Genentech USA, Inc. | 2 | $124 |
| AbbVie | 1 | $32 |
| AstraZeneca | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,391 in reported general payments places this provider in the 70th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 39 | $691,702 |
| LorbrenaLorlatinib | 13 | $199,685 |
| LumakrasSotorasib | 11 | $144,771 |
| EliquisApixaban | 16 | $9,587 |
| Dexamethasone | 42 | $507 |
| Ondansetron Hcl | 40 | $479 |
| Prochlorperazine Maleate | 33 | $434 |
| Olanzapine | 17 | $384 |
| Potassium Chloride | 12 | $359 |
| Gabapentin | 15 | $309 |
| Triamcinolone Acetonide | 20 | $285 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $276 |
| Oxycodone Hcl | 25 | $240 |
| Mirtazapine | 15 | $184 |
| Levothyroxine Sodium | 13 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $23 | $691,70239 claims |
| PfizerLorbrena, Eliquis | $1,440 | $209,27329 claims |
| Lilly USA, LLCOlanzapine | $1,150 | $38417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.